Rapid Communication

The Beta-Arrestin-Biased Dopamine D₂ Receptor Ligand, UNC9994, Is a Partial Agonist at G-Protein-Mediated Potassium Channel Activation

Richard Ågren, Peter Århem, Johanna Nilsson, Kristoffer Sahlholm

Department of Neuroscience (Drs Ågren, Århem, Nilsson, and Sahlholm), and Department of Clinical Neuroscience (Drs Ågren and Nilsson), Karolinska Institutet, Stockholm, Sweden.

J.N. and K.S. have equal senior contribution.

Correspondence: Kristoffer Sahlholm, PhD, Department of Neuroscience, Karolinska Institutet, Retzius väg 8, 17177, Stockholm, Sweden (kristoffer.sahlholm@ki.se).

Abstract

Background: Previous evidence suggests that UNC9994 is a beta-arrestin2-selective agonist at the dopamine D₂ receptor, lacking ability both to activate and antagonize G protein-dependent signaling. However, this has only been reported by one laboratory using a single assay.

Methods: We used G protein-coupled inward rectifier potassium channel activation in Xenopus oocytes to investigate UNC9994-induced modulation of G protein-dependent signaling at dopamine D₂ receptor and dopamine D₃ receptor.

Results: At dopamine D₂ receptor, UNC9994 induced G protein-coupled inward rectifier potassium channel currents that were 15% of the maximal response to dopamine, with an EC₅₀ of 185 nM. At dopamine D₃ receptor, the ligand elicited 89% of the maximal dopamine response with an EC₅₀ of 62 nM. Pertussis toxin abolished G protein-coupled inward rectifier potassium channel activation. Furthermore, UNC9994 antagonized dopamine-induced G protein-coupled inward rectifier potassium channel activation at dopamine D₂ receptor.

Conclusions: UNC9994 modulates G protein-coupled inward rectifier potassium channel channel activation via pertussis toxin-sensitive G proteins at dopamine D₂ receptor and dopamine D₃ receptor. These findings may have implications for the interpretation of data obtained with this ligand.

KeyWords: antipsychotic, arrestin, beta-arrestin2, biased ligand, electrophysiology

Introduction

A major challenge to effective treatment of psychotic disorders (including schizophrenia, schizoaffective disorder, and bipolar disorder with mania) is the occurrence of adverse reactions, such as extrapyramidal side-effects, to antipsychotic drugs. These side-effects lead to high rates of treatment nonadherence, thus limiting the clinical usefulness of current antipsychotics. Furthermore, whereas existing drugs show efficacy against the so-called positive symptoms of schizophrenia (i.e., delusions and hallucinations), current treatment does not adequately address the negative (e.g., social withdrawal, emotional flattening, avolition) and cognitive symptom domains (Miyamoto et al., 2012).

Current antipsychotics are antagonists or weak partial agonists (which may be functionally selective; see Urban et al., 2007) at dopamine D₂ and D₃ receptors (D₂R and D₃R). These receptors are known to signal via several downstream pathways, which
include the classical G protein pathway and the more recently described arrestin pathway (Beaulieu and Gainetdinov, 2011). G protein-mediated actions include adenylate cyclase inhibition and activation of G protein-coupled inward rectifier (GIRK) channels, whereas arrestin recruitment to the receptor, apart from desensitization and internalization, initiates a distinct signaling cascade, which involves Akt/PKB and glycogen synthase-kinase 3. β-Arrestin2 (also known as arrestin3) has specifically been implicated as the arrestin isoform regulating D_R downstream signaling (Beaulieu et al., 2005).

The importance of arrestin signaling has come to the forefront of schizophrenia research in recent years (Freyberg et al., 2010). All clinically used antipsychotics antagonize arrestin recruitment to the D_R (Klew et al., 2008; Marri et al., 2008), suggesting that this mechanism might be relevant for their therapeutic activity. Indeed, it has been proposed that the clinical benefits of antipsychotics are mediated mainly via inhibition of the arrestin pathway, whereas attenuation of G protein activation would be responsible for extrapyramidal side-effects (Allen et al., 2011). Accordingly, efforts are underway to develop D_R ligands that specifically modulate arrestin signaling (Urs et al., 2016; Männel et al., 2017; McCorvy et al., 2018).

Recent data suggest that “arrestin-biased” ligands, which act as partial agonists on the arrestin pathway without affecting G protein activity, such as UNC9994 (Allen et al., 2011), are able to restore rodent behavioral deficits induced by phencyclidine (PCP) and amphetamine; 2 pharmacological models frequently used for detecting antipsychotic efficacy (Urs et al., 2016). Acting via D_R, UNC9994 appears to activate arrestin-dependent signaling preferentially in cortex (Urs et al., 2016), presumably due to the high expression of both β-arrestin2 and G protein receptor kinase-2 (GRK2) in this brain region enhancing D2R coupling to this pathway (Urs et al., 2016; Sahilholm et al., 2017). The resulting action in the striatum, where β-arrestin2 and GRK2 expression is lower, remains less defined but appears to contribute to antipsychotic-like efficacy in the amphetamine and PCP models (Urs et al., 2016; Sahilholm et al., 2018). It has been suggested that such an action could substitute for the frontal cortical hypodopaminergia believed to underlie cognitive and negative symptoms in schizophrenia while simultaneously counterbalancing excessive D_R signaling in the striatum, thought to cause positive symptoms (Urs et al., 2016). Motor side-effects could potentially be avoided by leaving G protein signaling intact (Allen et al., 2011). However, there are some notable weaknesses and contradictions to these hypotheses; clinical evidence suggests that hypofunction of prefrontal cortical D_R, rather than D_R, may be involved in cognitive deficits in schizophrenia (Arnsten et al., 2017), and activation of both cortical and striatal D_Rs may contribute to the production of positive symptoms (Arnsten et al., 2015). In addition, aripiprazole, which does interfere with G-protein-dependent D_R signaling (Allen et al., 2011; Urs et al., 2016), has a very favorable motor side-effect profile (Naber and Lambert, 2004).

Remarkably, UNC9994 was reported not only to be completely devoid of agonist activity in assays of D_R-mediated G protein activation but was also found to lack the ability to antagonize dopamine-induced inhibition of adenylate cyclase activity at D_R (Urs et al., 2016). It was thus suggested that UNC9994 might be able to interact only with arrestin-coupled- but not G protein-coupled D_R, making it a truly “arrestin-selective” ligand, which could theoretically allow for a mild side-effect profile as outlined above. However, the lack of antagonistic effects of UNC9994 on D_R-mediated G protein signaling has been described only on the basis of cAMP accumulation experiments, which lacked temporal resolution (GloSensor, a cAMP assay; Urs et al., 2016). Furthermore, while UNC9994 is a relatively low-potency ligand with an EC_50 of 0.45 to 1 µM in some arrestin recruitment assays (Allen et al., 2011), only concentrations up to 1 µM of UNC9994 were tested in the GloSensor experiments when competing against dopamine (Urs et al., 2016).

While a completely signaling pathway-selective D_R ligand would be of great utility to the field of neuropharmacology, purportedly arrestin-selective ligands for other receptors, such as the angiotensin-I receptor agonist, SII, have recently been shown to be partial agonists in G protein activation assays (Grundmann et al., 2018), underscoring the need for independent validation. To further investigate the interaction (or lack thereof) of UNC9994 with G protein-dependent signaling, we examined the activity of this ligand toward D_R- and D_R-mediated activation of GIRK channels, a sensitive and time-resolved assay that has previously allowed us to study weak partial D_R agonists (Sahilholm et al., 2011).

Methods

Molecular Biology

Human GIRK1 (Kir3.1) and GIRK4 (Kir3.4) cDNA (provided by Dr. Terence Hebert, University of Montreal, Canada) and Regulators of G protein Signaling (RGS)4 (from the Missouri cDNA Resource Center; www.cdna.org) were in pcDNA3 (Invitrogen). cDNA encoding the human dopamine D_R (long isoform of D_R) and D_R receptors and human beta-arrestin2 was in pXOOM (from Dr. Søren-Peter Oleen, University of Copenhagen, Denmark), and the catalytic subunit of PTX (PTX-S1; from Dr. Eitan Reuveny, Weizmann Institute of Science, Israel) was in pGEM-HE. For in vitro transcription, plasmids were linearized (GIRK 1/4, NotI; RGS4, D_R and D_R, XhoI; PTX-S1, NheI) and transcribed in vitro using the T7 mMessage mMachine kit (Ambion, Austin, TX). cRNA concentration and purity were determined using a spectrophotometer.
Oocytes were surgically isolated from female African clawed toads, *Xenopus laevis*, and injected with cRNA as previously described (Sahlholm et al., 2011). The surgical procedures had been approved by the Swedish National Board for Laboratory Animals and the local ethics committee, Stockholms Norra Djurförsöksetiska nämnd. One nanogram of each GIRK subunit cRNA, 0.2 ng of dopamine D2 or D3 receptor cRNA, and, when used, 40 ng of RGS4, 5.6 ng of beta-arrestin2, and 3 ng of PTX-S1 cRNA were injected per oocyte. RGS proteins are GTPase-activating proteins expressed in native tissues, which speed up the G protein cycle such that GIRK channel activity more closely follows receptor occupancy by agonist (Dascal and Kahanovitch, 2015).

Receptor Ligands

Dopamine was purchased from Sigma-Aldrich (St. Louis, MO) and UNC9994 and aripiprazole were from Axon MedChem BV (Groeningen, The Netherlands). Dopamine was dissolved in recording buffer, whereas UNC9994 was dissolved in DMSO. (-)-3PPP was a gift from Astra Zeneca (Södertälje, Sweden). Ligands were diluted in the recording solution to obtain the desired concentrations. The maximum final concentration of DMSO used in any experiment did not exceed 0.1% v/v.

Electrophysiology

The electrophysiological experiments were performed at room temperature (20–22°C) 5 to 7 days after cRNA injection using a 2-electrode voltage-clamp setup (CA-1 amplifier, Dagan, Minneapolis, MN) as previously described (Sahlholm et al., 2011). Data were acquired at 134 Hz using pCLAMP 8 (Molecular Devices) software. A high-potassium solution (in mM: 64 NaCl, 20 KCl, 0.8 MgCl2, 0.4 CaCl2, 15 HEPES, 1 ascorbic acid, adjusted to pH 7.4), giving a K+ reversal potential of about -40 mV, was used for GIRK current recording. Ascorbic acid was present to prevent the oxidation of dopamine. Single -80 mV pulses were applied to study GIRK current responses to D,R activity. Ligands were added to the 20-μL recording chamber by superfusion at 1.5 mL/min using a computer-controlled, pressure-driven perfusion system (SmartSquirt, AutoMate Scientific, Berkeley, CA). When evaluating UNC9994 in the agonist mode, 3 to 4 increasing concentrations of the ligand were applied at 35- or 50-second intervals to oocytes expressing D2R or D3R, respectively. The UNC9994-evoked current response was determined by subtracting the basal (agonist-independent) current from the experimental record. The UCN9994-induced current responses were subsequently normalized to the mean response to 1 μM dopamine in 4 different oocytes (expressing D2R or D3R, respectively, together with RGS4 and GIRK1/4), which had not previously been exposed to UNC. In the agonist mode, 100 nM dopamine was first applied to provide a baseline response, followed by 3 to 4 applications of increasing concentrations of UNC9994 at 50-second intervals in the continued presence of dopamine. For each oocyte, the current amplitude at the end of each antagonist application interval was normalized to the control response to 100 nM dopamine obtained at the start of the protocol. For dopamine concentration-response data, 4 to 5 increasing concentrations of dopamine were applied at 25-second intervals, ending with a response-saturating concentration (100 μM) of dopamine (supplementary Figure 1).

Data Analysis

Variable slope sigmoidal concentration-response curves were fitted to the concentration-response data using GraphPad (Prism Software). The following equation was fitted to agonist data:

\[ Y = \text{top} / \left(1 + 10^{(\log EC_{50} - X) \times n}\right), \]

where \( Y \) is the response as a fraction of 1, \( \text{top} \) is the maximal response, of the agonist expressed as a fraction of 1, \( X \) is the logarithm of ligand concentration, and \( n \) is the Hill slope.

For fitting antagonist data, the fitted equation was:

\[ Y = \text{bottom} + \left(\text{top} - \text{bottom}\right) / \left(1 + 10^{(\log EC_{50}? X) \times n}\right), \]

where \( \text{bottom} \) is the maximal response inhibition evoked by the antagonist.

Results

First, UNC9994 was applied alone to *Xenopus* oocytes expressing D3R together with RGS4 and GIRK1/4 channels. The ligand evoked small but clearly detectable inward currents when applied at concentrations between 10 nM and 10 μM (Figure 1A). Such currents were not observed when UNC9994 was applied to oocytes injected with RNA encoding D2R but not GIRK1/4, nor in oocytes expressing GIRK channels alone (not shown), and were abolished by coexpression of the catalytic subunit of pertussis toxin (PTX-S1; Figure 1A, inset), which inactivates inhibitory Gαi proteins by ADP ribosylation (Vivaudou et al., 1997). The pEC50 for UNC9994-induced current activation was 6.73 ± 0.40 (EC50 185 nM; comparable with the K of 79 nM of this compound at D2R, as reported by Allen et al., 2011). The top of the UNC9994 concentration-response curve was 14.5 ± 2.8% of the mean response to 1 μM dopamine (which evokes a maximal response; see supplementary Figure 1), indicating weak partial agonism of UNC9994 at GIRK activation elicited via D3R (Figure 1B). The similarly submaximal responses elicited by 10 μM of the known partial D2R agonists, (-)-3-PPP and aripiprazole, which evoked 27.7 ± 7.5 and 9.2 ± 2.3% of the mean response to 1 μM dopamine, respectively (supplementary Figure 2), suggest that the receptor reserve under these conditions was low or absent.

When applied to oocytes expressing D3R together with RGS4 and GIRK1/4 channels, the efficacy of UNC9994 was greater than at D2R (Figure 1B), evoking 89.1 ± 24.3% of the maximal response to 1 μM dopamine. In agreement with radioligand competition data reported by Allen et al. (2011), the functional potency of UNC9994 was higher at the D2R that at the D3R, with a pEC50 of 6.21 ± 0.55 (EC50 62.1 nM). PTX-S1 coexpression prevented UNC9994-induced GIRK activation also in D2R-expression oocytes (data not shown).

When applied to oocytes expressing D3R together with RGS4 and GIRK1/4 channels in the presence of 100 nM dopamine, UNC9994 inhibited the dopamine-induced response with an IC50 of 630 nM (Figure 1C, D). Assuming a K of dopamine of 33 nM based on its EC50 value for GIRK channel activation (supplementary Figure 1), the K of UNC9994 was estimated as 155 nM, again comparable with the K reported by Allen et al. (2011).

Finally, we evaluated the effects of UNC9994 in oocytes expressing D3R together with GIRK1/4 and beta-arrestin2. The expression levels of beta-arrestin2 were sufficiently high to induce prominent desensitization of the response to 1 μM dopamine.
dopamine compared with control cells, which had not been injected with RNA encoding beta-arrestin2 (Figure 2A, B). A total of 10 μM UNC9994 was found to induce GIRK activation also under these conditions, which was 21.7 ± 9.1% of the mean response to 1 μM dopamine (Figure 2C, D).

**Discussion**

UNC9994 has previously been described as an arrestin-biased ligand incapable of activating G protein-dependent signaling downstream of D₃R (Allen et al., 2011) and, even more intriguingly, unable to antagonize dopamine-evoked adenylate cyclase inhibition via this receptor (Urs et al., 2016). It should be emphasized that the present study does not address the relative efficacies of G protein- vs arrestin-dependent signaling elicited by UNC9994. Rather, our results challenge previous reports of a complete lack of interaction of UNC9994 with G protein-dependent signaling, as the present findings strongly suggest that this compound acts as an agonist at GIRK channel activation at D₂R and D₃R. GIRK channels are typically activated by Gₛᵣ.
subunits released from G\textsubscript{i/o} proteins (Dascal and Kahanovitch, 2015). In accordance with a G\textsubscript{i/o}-dependent process, GIRK activation by UNC9994 was blocked by coexpression of the catalytic subunit of PTX (Vivaudou et al., 1997). Furthermore, we showed that at the D\textsubscript{2}R, where the efficacy of UNC9994 is low, this ligand antagonizes the near-maximal GIRK response induced by 100 nM dopamine. Xenopus oocytes do not endogenously express functional arrestins (Kovoor et al., 1997); however, we found UNC9994 to elicit GIRK activation also in oocytes expressing human beta-arrestin2.

The reasons for the discrepancy between the present work and earlier published findings by Allen et al. (2011) and Urs et al. (2016) are unclear at present, but may, in part, reflect functional selectivity for GIRK channel activation over adenylate cyclase inhibition. Such selectivity has been reported previously for the antipsychotic aripiprazole and its analogue, SV-III-130s, which are both structurally related to UNC9994. Opposite to UNC9994, aripiprazole and SV-III-130s were found to be partial agonists in adenylate cyclase inhibition assays while acting as neutral antagonists when D\textsubscript{2}R-mediated GIRK channel activation was examined (Urban et al., 2007; Luedtke et al., 2012). Here, however, aripiprazole was found to be a partial agonist at GIRK activation, with an efficacy similar to that of UNC9994. Interestingly, aripiprazole and UNC9994 were shown to have similar efficacy also at beta-arrestin signaling (Urs et al., 2017), which could suggest that, when considering GIRK activation as the read-out of G\textsubscript{i/o} activity, there is little difference in arrestin/G protein bias between the 2 compounds. However, bias is context dependent and should be investigated in the same cellular background and at the same time-point following agonist addition (Klein Herenbrink et al., 2016; Onfroy et al., 2017). Measures of biased agonism, as well as antagonism, have been reported to be strongly influenced by the stoichiometry of receptor, G protein, and effector molecules (Onfroy et al., 2017), and these parameters likely differed between our study and those of Urs et al. (2016) and Allen et al. (2011), which may have contributed to the divergent results. For example, a large receptor reserve in the experiments by Urs et al. (2016) may have precluded the detection of antagonism at 1 \textmu M UNC9994, which was the highest concentration tested. In addition, the lack of temporal resolution of the adenylate cyclase assay might have prevented observation of a modulatory effect of UNC9994 (see Klein Herenbrink et al., 2016, for an investigation of the effect of incubation time on measures of ligand efficacy).

Nevertheless, the absence of antagonism of G protein-dependent signaling reported by Urs et al. (2016) stands in sharp contrast to the present data, and our findings may thus warrant reinterpretation of some of the findings reported from studies where UNC9994 was used as an arrestin-specific ligand (e.g., Scarduzio et al., 2017; Pack et al., 2018). The abolition of

**Figure 2.** UNC9994 acts as a partial agonist at G protein-coupled inward rectifier (GIRK) activation also in the presence of beta-arrestin2. (A) Representative current traces recorded from oocytes coexpressing dopamine D\textsubscript{2} receptor (D\textsubscript{2}R) with GIRK1/4 channels with or without beta-arrestin2, as indicated, demonstrating the impact of beta-arrestin2 coexpression on the time course of the current response to 1 \textmu M dopamine. (B) Ratio between the peak inward current response and the response amplitude at the end of the 240-second application of dopamine. **P < .01, Student’s t test, n = 5 for each group of oocytes. (C) Representative current trace showing GIRK channel activation elicited upon application of 10 \textmu M UNC9994 (UNC) in an oocyte coexpressing D\textsubscript{2}R with GIRK1/4 channels and beta-arrestin2. (D) Average response to 10 \textmu M UNC9994 as a fraction of the average response to 1 \textmu M dopamine in oocytes coexpressing D\textsubscript{2}R with GIRK1/4 channels and beta-arrestin2. n = 6 for UNC9994; n = 5 for dopamine.
antipsychotic-like activity of this ligand in beta-arrestin2 knock-out animals certainly suggests an important contribution of the arrestin pathway to such activity (Allen et al., 2011); however, it cannot be excluded that G protein-dependent signaling also plays some role. This is particularly relevant considering that arrestin signaling was suggested to be low or absent in striatal medium spiny neurons (Urs et al., 2016), yet A_	ext{R}-expressing neurons, which are mainly of this type, appear to play a role in the ability of UNC9994 to counteract amphetamine- and PCP-induced hyperlocomotion (Sahilholm et al., 2018; Urs et al., 2016). Furthermore, UNC9994 has higher affinity for D_	ext{R} than for D_	ext{R} (Allen et al., 2011), and the G protein-dependent agonist activity of UNC9994 at D_	ext{R} revealed in the present study may confer pro-cognitive properties similar to those described for the similarly D_	ext{R}-preferring antipsychotic, cariprazine (Zimnisky et al., 2013; Németh et al., 2017).

In summary, our present findings suggest that UNC9994 is able to induce G protein-dependent GIRK activation via D_	ext{R} and D_	ext{R}, acting as a weak partial agonist at the former while being more efficacious at the latter receptor. In addition, contrasting with previous findings examining adenylate cyclase activity, UNC9994 inhibits the G protein-dependent GIRK response to dopamine via D_	ext{R}.

### Supplementary Materials

Supplementary data are available at The International Journal of Neuropsychopharmacology online.

### Funding

This work was supported by research grants from Stiftelsen Lars Hiertas Minne (FO2016-0434 to K.S.), Åhlén-stiftelsen (no grant number, to K.S.), Magnus Bergvalls stiftelse (2016-01785-01-4 to J.N.).

### Acknowledgments

K.S. is a recipient of postdoctoral fellowships from the Swedish Brain Foundation (SLS-687851). (-)-3PPP was a gift from Astra Zeneca (Södertälje, Sweden).

### Statement of Interest

None.

### References

Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, Feng B, Jensen NH, Che X, Bai X, Frye SV, Wetzel WC, Caron MG, Javitch JA, Roth BL, Jin J (2011) Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A 108:18488–18493.

Arnsten AF, Wang M, Paspalas CD (2015) Dopamine’s actions in primate prefrontal cortex: challenges for treating cognitive disorders. Pharmacol Rev 67:681–696.

Arnsten AF, Girgis RR, Gray DL, Mailman RB (2017) Novel dopamine therapeutics for cognitive deficits in schizophrenia. Biol Psychiatry 81:67–77.

Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182–217.

Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005) An akt-beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261–273.

Dascal N, Kahanovitch U (2015) The roles of gγi and gαi in gating and regulation of GIRK channels. Int Rev Neurobiol 123:27–85.

Freyberg Z, Ferrando SJ, Javitch JA (2010) Roles of the akt/GSK-3 and wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 167:388–396.

Grundmann M, et al (2018) Lack of beta-arrestin signaling in the absence of active G proteins. Nat Commun 9:341.

Klein Herenbrink C, Sykes DA, Domhanametti P, Canals M, Coudrat T, Shonberg J, Scammells PJ, Capuano B, Sexton PM, Charlton SJ, Javitch JA, Christopoulos A, Lane JR (2016) The role of kinetic context in apparent biased agonism at gpcrs. Nat Commun 7:10842.

Klewe IV, Nielsen SM, Tarpe L, Urizar E, Dipace C, Javitch JA, Gether U, Egebjerg J, Christensen KV (2008) Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropsychopharmacology 54:1215–1222.

Kviovor A, Nappey V, Kieffer BL, Chavkin C (1997) Mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in Xenopus oocytes. J Biol Chem 272:27605–27611.

Luedtke RR, Mishra Y, Wang Q, Griffin SA, Bell-Horner C, Taylor M, Vangervavong S, Dillon GH, Huang RQ, Reichert DE, Mach RH (2012) Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds. ACS Chem Neurosci 3:1050–1062.

Männel B, Jaiteh M, Zeifman A, Randakova A, Möller D, Hübner H, Gmeiner P, Carlsson J (2017) Structure-guided screening for functionally selective D2 dopamine receptor ligands from a virtual chemical library. ACS Chem Biol 12:2652–2661.

Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, Caron MG (2008) Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A 105:13656–13661.

McCorvy JD, Butler KV, Kelly B, Rechsteiner K, Karpiaj J, Betz RM, Kormos BL, Shoichet BK, Dror RO, Jin J, Roth BL (2018) Structure-inspired design of β-arrestin-biased ligands for aminergic gpcrs. Nat Chem Biol 14:126–134.

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17:1206–1227.

Naber D, Lambert M (2004) Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 28:1213–1219.

Németh G, Laszlovszky J, Czobor P, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW (2017) Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet 389:1103–1113.

Onfroy L, Galandrin S, Pontier SM, Seguelas MH, N’Guyen D, Sénard JM, Galés C (2017) G protein stoichiometry dictates biased agonism through distinct receptor-G protein partitioning. Sci Rep 7:7885.
Pack TF, Orlen MI, Ray C, Peterson SM, Caron MG (2018) The dopamine D2 receptor can directly recruit and activate GRK2 without G protein activation. J Biol Chem 293:6161–6171.
Sahilholm K, Barchad-Avitzur O, Marcellino D, Gómez-Soler M, Fuxe K, Ciruela F, Arhem P (2011) Agonist-specific voltage sensitivity at the dopamine D2S receptor–molecular determinants and relevance to therapeutic ligands. Neuropharmacology 61:937–949.
Sahilholm K, Ielacqua GD, Xu J, Jones LA, Schlegel F, Mach RH, Rudin M, Schroeter A (2017) The role of beta-arrestin2 in shaping fMRI BOLD responses to dopaminergic stimulation. Psychopharmacology (Berl) 234:2019–2030.
Sahilholm K, Gómez-Soler M, Valle-León M, López-Cano M, Taura JJ, Ciruela F, Fernández-Dueñas V (2018) Antipsychotic-like efficacy of dopamine D2 receptor-biased ligands is dependent on adenosine A2A receptor expression. Mol Neurobiol 55:4952–4958.
Scarduzio M, Zimmerman CN, Jaunarajs KL, Wang Q, Standaert DG, McMahon LL (2017) Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia. Exp Neurol 295:162–175.
Vivaudou M, Chan KW, Sui JL, Jan LY, Reuveny E, Logothetis DE (1997) Probing the G-protein regulation of GIRK1 and GIRK4, the two subunits of the kach channel, using functional homomeric mutants. J Biol Chem 272:31553–31560.
Urban JD, Vargas GA, von Zastrow M, Mailman RB (2007) Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32:67–77.
Urs NM, Gee SM, Pack TF, McCorvy JD, Evron T, Snyder JC, Yang X, Rodriguiz RM, Borrelli E, Wetsel WC, Jin J, Roth BL, O’Donnell P, Caron MG (2016) Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties. Proc Natl Acad Sci U S A 113:E8178–E8186.
Urs NM, Peterson SM, Caron MG (2017) New concepts in dopamine D2 receptor biased signaling and implications for schizophrenia therapy. Biol Psychiatry 81:78–85.
Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C (2013) Cariprazine, a dopamine D(3)-receptor-prefering partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl) 226:91–100.